LON:CEL Celadon Pharmaceuticals (CEL) Share Price, News & Analysis GBX 13.40 0.00 (0.00%) As of 08/6/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesBuy This Stock About Celadon Pharmaceuticals Stock (LON:CEL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CEL alerts:Sign Up Key Stats Today's Range 13.40▼ 13.4050-Day Range 8.48▼ 1552-Week Range 2.21▼ 83VolumeN/AAverage Volume226,267 shsMarket Capitalization£8.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder. For further information please visit our website www.celadonpharma.com Read More Receive CEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CEL Stock News HeadlinesCeladon Pharmaceuticals Passes AGM Resolutions and Plans DelistingJuly 1, 2025 | tipranks.comAIM WINNERS & LOSERS: Celadon jumps; Frasers eyes Revolution BeautyJune 9, 2025 | lse.co.ukMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks. | American Alternative (Ad)Celadon Pharmaceuticals Faces Financial Uncertainty Amid Funding EffortsJune 6, 2025 | tipranks.comCeladon Pharmaceuticals faces potential administrationJune 1, 2025 | investing.comCeladon Pharmaceuticals Faces Financial Uncertainty Amid Funding ChallengesMay 30, 2025 | tipranks.comCeladon Pharmaceuticals Terminates Credit Facility Amid Strategic Financial AdjustmentsApril 8, 2025 | tipranks.comCeladon Pharmaceuticals Faces Financial Uncertainty Amid Funding DelaysMarch 31, 2025 | tipranks.comSee More Headlines CEL Stock Analysis - Frequently Asked Questions How have CEL shares performed this year? Celadon Pharmaceuticals' stock was trading at GBX 14 at the start of the year. Since then, CEL stock has decreased by 4.3% and is now trading at GBX 13.40. How do I buy shares of Celadon Pharmaceuticals? Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Celadon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celadon Pharmaceuticals investors own include AutoZone (AZO), Bahamas Petroleum (BPC), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM) and Bank of America (BAC). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryCommunication Current SymbolLON:CEL CIKN/A Webwww.celadonpharma.co.uk Phone44 20 3150 0252FaxN/AEmployees2,780Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (7.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£4.97 million Net Margins-4,024.62% Pretax MarginN/A Return on Equity-187.26% Return on Assets-34.40% Debt Debt-to-Equity Ratio196.67 Current Ratio1.92 Quick Ratio6.97 Sales & Book Value Annual Sales£123.38 thousand Price / Sales66.61 Cash FlowGBX 4.39 per share Price / Cash Flow3.05 Book ValueGBX 3.80 per share Price / Book3.53Miscellaneous Outstanding Shares61,329,971Free FloatN/AMarket Cap£8.22 million OptionableNot Optionable Beta-0.26 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (LON:CEL) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFOUR TRILLION DOLLARS!Nvidia just became the first company in history to hit a $4 trillion valuation—surpassing Apple and Microsoft....Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.